This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hussain, S. P. Articles by Harris, C. C. Search for Related Content PubMed PubMed Citation Articles by Hussain, S. P. Articles by Harris, C. C.

Mutability of p53 Hotspot Codons to Benzo(a)pyrene Diol Epoxide (BPDE) and the Frequency of p53 Mutations in Nontumorous Human Lung

Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892

p53 mutations are common in lung cancer. In smoking-associated lung cancer,the occurrence of G:C to T:A transversions at hotspot codons, e.g., 157, 248, 249,and 273, has been linked to the presence of carcinogenic chemicalsin tobacco smoke including polycyclic aromatic hydrocarbons suchas benzo(a)pyrene (BP). In the present study, we have used a highly sensitive mutation assay to determine the p53 mutation load in nontumorous human lung and to study the mutability of p53 codons 157, 248, 249, and 250 to benzo(a)pyrene-diol-epoxide (BPDE), an active metabolite of BP in human bronchial epithelial BEAS-2B cells. We determined the p53 mutational load at codons 157, 248, 249, and 250 in nontumorous peripheral lung tissue either from lung cancer cases among smokers or noncancer controls among smokers and nonsmokers. A 5–25-fold higher frequency of GTC^val to TTC^phe transversions at codon 157 was found in nontumorous samples (57%) from cancer cases (n = 14) when compared with noncancer controls (n = 8; P < 0.01). Fifty percent (7/14) of the nontumorous samples from lung cancer cases showed a high frequency of codon 249 AGG^arg to AGT^ser mutations (P < 0.02). Four of these seven samples with AGT^ser mutations also showed a high frequency of codon 249 AGG^arg to ATG^met mutations, whereas only one sample showed a codon 250 CCC to ACC transversion. Tumor tissue from these lung cancer cases (38%) contained p53 mutations but were different from the above mutations found in the nontumorous pair. Noncancer control samples from smokers or nonsmokers did not contain any detectable mutations at codons 248, 249, or 250. BEAS-2B bronchial epithelial cells exposed to doses of 0.125, 0.5, and 1.0 µM BPDE, showed G:C to T:A transversions at codon 157 at a frequency of 3.5 x 10^-7, 4.4 x 10^-7, and 8.9 x 10^-7, respectively. No mutations at codon 157 were found in the DMSO-treated controls. These doses of BPDE induced higher frequencies, ranging from 4–12-fold, of G:C to T:A transversions at codon 248, G:C to T:A transversions and G:C to A:T transitions at codon 249, and C:G to T:A transitions at codon 250 when compared with the DMSO-treated controls. These data are consistent with the hypothesis that chemical carcinogens such as BP in cigarette smoke cause G:C to T:A transversions at p53 codons 157, 248, and 249 and that nontumorous lung tissues from smokers with lung cancer carry a high p53 mutational load at these codons.

This article has been cited by other articles:

				L. Anna, R. Holmila, K. Kovacs, E. Gyorffy, Z. Gyori, J. Segesdi, J. Minarovits, I. Soltesz, S. Kostic, A. Csekeo, et al. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary Mutagenesis, November 1, 2009; 24(6): 475 - 480. [Abstract] [Full Text] [PDF]

				N. Hagiwara, L. E. Mechanic, G. E. Trivers, H. L. Cawley, M. Taga, E. D. Bowman, K. Kumamoto, P. He, M. Bernard, S. Doja, et al. Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers Cancer Res., August 15, 2006; 66(16): 8309 - 8317. [Abstract] [Full Text] [PDF]

				A. Besaratinia and G. P. Pfeifer Investigating human cancer etiology by DNA lesion footprinting and mutagenicity analysis Carcinogenesis, August 1, 2006; 27(8): 1526 - 1537. [Abstract] [Full Text] [PDF]

				S. Choudhary, K. M. Doherty, C. J. Handy, J. M. Sayer, H. Yagi, D. M. Jerina, and R. M. Brosh Jr. Inhibition of Werner Syndrome Helicase Activity by Benzo[a]pyrene Diol Epoxide Adducts Can Be Overcome by Replication Protein A J. Biol. Chem., March 3, 2006; 281(9): 6000 - 6009. [Abstract] [Full Text] [PDF]

				P. Vineis and K. Husgafvel-Pursiainen Air pollution and cancer: biomarker studies in human populations Carcinogenesis, November 1, 2005; 26(11): 1846 - 1855. [Abstract] [Full Text] [PDF]

				F. Le Calvez, A. Mukeria, J. D. Hunt, O. Kelm, R. J. Hung, P. Taniere, P. Brennan, P. Boffetta, D. G. Zaridze, and P. Hainaut TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers Cancer Res., June 15, 2005; 65(12): 5076 - 5083. [Abstract] [Full Text] [PDF]

				Y. Hu, M. P. McDermott, and S. A. Ahrendt The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2502 - 2509. [Abstract] [Full Text] [PDF]

				R. Meuwissen and A. Berns Mouse models for human lung cancer Genes & Dev., March 15, 2005; 19(6): 643 - 664. [Abstract] [Full Text] [PDF]

				L. E. Mechanic, A. J. Marrogi, J. A. Welsh, E. D. Bowman, M. A. Khan, L. Enewold, Y.-L. Zheng, S. Chanock, P. G. Shields, and C. C. Harris Polymorphisms in XPD and TP53 and mutation in human lung cancer Carcinogenesis, March 1, 2005; 26(3): 597 - 604. [Abstract] [Full Text] [PDF]

				J.-H. Yoon, A. Besaratinia, Z. Feng, M.-s. Tang, S. Amin, A. Luch, and G. P. Pfeifer DNA Damage, Repair, and Mutation Induction by (+)-Syn and (-)-Anti-Dibenzo[a,l]Pyrene-11,12-Diol-13,14-Epoxides in Mouse Cells Cancer Res., October 15, 2004; 64(20): 7321 - 7328. [Abstract] [Full Text] [PDF]

				Aspen Cancer Conference Fellows Toxicol Pathol, October 1, 2004; 32(6): 749 - 761. [PDF]

				K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]

				A. Matakidou, T. Eisen, and R.S. Houlston TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis Mutagenesis, July 1, 2003; 18(4): 377 - 385. [Abstract] [Full Text] [PDF]

				A. Yamane, K. Shinmura, N. Sunaga, T. Saitoh, S. Yamaguchi, Y. Shinmura, K. Yoshimura, H. Murakami, Y. Nojima, T. Kohno, et al. Suppressive activities of OGG1 and MYH proteins against G:C to T:A mutations caused by 8-hydroxyguanine but not by benzo[a]pyrene diol epoxide in human cells in vivo Carcinogenesis, June 1, 2003; 24(6): 1031 - 1037. [Abstract] [Full Text] [PDF]

				J.-H. Yoon, C.-S. Lee, and G. P. Pfeifer Simulated sunlight and benzo[a]pyrene diol epoxide induced mutagenesis in the human p53 gene evaluated by the yeast functional assay: lack of correspondence to tumor mutation spectra Carcinogenesis, January 1, 2003; 24(1): 113 - 119. [Abstract] [Full Text] [PDF]

				K. Alexandrov, I. Cascorbi, M. Rojas, G. Bouvier, E. Kriek, and H. Bartsch CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation Carcinogenesis, December 1, 2002; 23(12): 1969 - 1977. [Abstract] [Full Text] [PDF]

				A. Besaratinia, L.M. Maas, E.M.C. Brouwer, E.J.C. Moonen, T.M.C.M. De Kok, G.J. Wesseling, S. Loft, J.C.S. Kleinjans, and F.J. Van Schooten A molecular dosimetry approach to assess human exposure to environmental tobacco smoke in pubs Carcinogenesis, July 1, 2002; 23(7): 1171 - 1176. [Abstract] [Full Text] [PDF]